Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis?

被引:32
|
作者
Liu, C [1 ]
Playford, ED [1 ]
Thompson, AJ [1 ]
机构
[1] UCL Natl Hosp Neurol & Neurosurg, Neurorehabil Unit, London WC1N 3BG, England
关键词
multiple sclerosis; rehabilitation; relapsing-remitting disability;
D O I
10.1007/s00415-003-0187-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Patients with relapsing-remitting multiple sclerosis (RR MS) often make incomplete recovery from disabling exacerbations, despite corticosteroid treatment. Inpatient rehabilitation has been shown to be valuable in progressive MS, but its role in RR MS is less clear. We evaluated the effect of rehabilitation in consecutive patients with RR MS admitted to a neurological rehabilitation unit. Outcome measures applied on admission and discharge included the Expanded Disability Status Scale (EDSS), the Barthel Index (BI) and the Functional Independence Measure (FIM), as well as a visual analogue scale (VAS) of the patients' perception of rehabilitation impact. Confounding factors including the timing of steroid therapy and re-admissions were also examined. RR patients showed considerable improvement following rehabilitation, with a median change of -0.5 on EDSS, +4 on BI and +12 on FIM (mean change of -0.8 EDSS, +4.5 BI and +15.6 FIM points; effect sizes of -1.01, 0.97 and 0.86, respectively), which was significantly greater than other MS subtypes. RR patients rated their admissions highly (median VAS 8.9, interquartile range 7.5-9.9), and the VAS scores correlated modestly with disability measures (Spearman's rho = -0.42, 0.31 and 0.24 versus EDSS, BI and FIM, respectively; p = 0.007-0.040). Repeat admissions and the timing of steroid treatment did not have a significant effect on outcome. This suggests that inpatient rehabilitation is useful in RR MS, particularly in patients with incomplete recovery from relapses who have accumulated moderate to severe disability.
引用
收藏
页码:1214 / 1218
页数:5
相关论文
共 50 条
  • [1] Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis?
    Clarence Liu
    E. Diane Playford
    Alan J. Thompson
    [J]. Journal of Neurology, 2003, 250 : 1214 - 1218
  • [2] Relapsing-remitting multiple sclerosis
    Flores, A
    Ochoa, E
    Zamora, S
    Barrientos, UN
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 214 (1-2) : 110 - 110
  • [3] Autohemotherapy for relapsing-remitting multiple sclerosis
    Mubaidin, AF
    Horani, KA
    Dehayyat, MA
    Shehab, M
    Abu-Ruman, IA
    Shurbaji, AA
    Kurdi, A
    Hiari, M
    Khakish, M
    Harahsheh, O
    Dabbas, M
    [J]. NEUROLOGY, 2001, 56 (08) : A75 - A75
  • [4] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Guo, Rui
    Zhang, Fubo
    Zhang, Chao
    Dong, Shuai
    Zhou, Hongyu
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [5] Relapsing-remitting tumefactive multiple sclerosis
    Selkirk, SM
    Shi, J
    [J]. MULTIPLE SCLEROSIS, 2005, 11 (06): : 731 - 734
  • [6] Depression in relapsing-remitting multiple sclerosis
    Mendes, MF
    Tilbery, CP
    Balsimelli, S
    Moreira, MA
    Barao-Cruz, AM
    [J]. ARQUIVOS DE NEURO-PSIQUIATRIA, 2003, 61 (3A) : 591 - 595
  • [7] Rituximab in relapsing-remitting multiple sclerosis
    Schrijver, Hans M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24): : 2645 - 2645
  • [8] Fingolimod for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Tramacere, Irene
    Firwana, Belal
    Pacchetti, Ilaria
    Palumbo, Roberto
    Filippini, Graziella
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [9] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [10] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Zhou, Hongyu
    Han, Wenjie
    Zhang, Shihong
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12):